What question did this study set out to answer?

To investigate clinical features and patient outcomes related to Rituximab induced acute thrombocytopenia in DLBCL patients.

December 8, 2025BloodOpen Access

Characteristics of diffuse large B-cell Lymphoma patients with rituximab induced acute thrombocytopenia

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis demonstrates platelet recovery post-Rituximab in DLBCL, highlighting clinical features and prognosis.

To investigate clinical features and patient outcomes related to Rituximab induced acute thrombocytopenia in DLBCL patients.
Retrospective study of newly diagnosed DLBCL patients receiving Rituximab from Jan 2020 to Dec 2023.
Assessment of blood counts within 3 days post-treatment in 671 patients to identify RIAT incidence.
Analysis of clinical features, efficacy, and prognosis of those with RIAT.
3.7% of patients experienced a platelet reduction of over 50% within 3 days after Rituximab administration.
At 24-month follow-up, overall survival rate was 81.8% and progression-free survival rate was 56.0%.
No deaths were reported during thrombocytopenia and bleeding events were uncommon.

Hongyan Tong (2025) studied this question.

View Full Paper

Ask AI

Bookmark